A single infusion of CTX310 slashed LDL cholesterol by 49% and triglycerides by 55% in Phase 1 trials — no daily pills, no side-effect treadmill. Larger trials begin this year as CRISPR moves from lab to clinic.
For millions of people who take cholesterol pills every single day of their lives — and for the millions more who cannot tolerate them — a technology that once sounded like science fiction is now producing real clinical results. CRISPR Therapeutics has reported landmark Phase 1 data for CTX310, a one-time gene-editing therapy that uses tiny lipid nanoparticles to carry the CRISPR-Cas9 editing mechanism directly into the liver. Once there, it permanently switches off a gene called ANGPTL3, which plays a central role in regulating both LDL cholesterol and triglycerides. In a 15-patient first-in-human trial conducted at the Cleveland Clinic and published in The New England Journal of Medicine, a single infusion of CTX310 at the highest dose reduced LDL cholesterol by an average of 49 percent and triglycerides by 55 percent. The maximum reductions were even more striking — 87 percent for LDL and 84 percent for triglycerides.
The results are historic for a reason that goes beyond the numbers. CTX310 is the first therapy ever to achieve large simultaneous reductions in both LDL cholesterol and triglycerides — the two lipid markers most strongly associated with cardiovascular disease, which remains the number one killer worldwide. Current treatments require patients to take statins, PCSK9 inhibitors, or fibrates on a daily or monthly basis, often for the rest of their lives. Many patients experience muscle pain, liver enzyme elevation, or gastrointestinal side effects that lead them to reduce doses or stop treatment entirely, leaving their cardiovascular risk unmanaged. CTX310 offers a fundamentally different proposition: a single-course treatment that produced durable reductions lasting at least 60 days in the trial, with both cholesterol and triglyceride levels dropping within two weeks of administration. The gene-editing approach is permanent by design — once ANGPTL3 is switched off, it stays off — which means the therapeutic effect is expected to last years or potentially a lifetime.
The safety profile in this small trial was clean, with no serious adverse events related to CTX310. But the real test comes next. CRISPR Therapeutics is launching larger Phase 2 trials in 2026 that will enrol hundreds of patients with difficult-to-treat lipid disorders — the people for whom statins alone are not enough. Meanwhile, the broader cardiac technology landscape is evolving at an unprecedented pace. At the American College of Cardiology meeting in March 2026, attendees saw live coronary CT angiography performed from a mobile semitruck, wearable devices capable of detecting early warning signs of cardiac events in real time, and new data on GLP-1 drugs showing heart-protective benefits beyond weight loss. AI is being deployed to automate the adjudication of cardiovascular trial endpoints, cutting costs and accelerating drug development timelines. Taken together, these advances represent a convergence of gene therapy, artificial intelligence, wearable monitoring, and precision medicine that is transforming cardiology from a field of chronic disease management into one of prevention and cure. For the hundreds of millions of people worldwide living with cardiovascular disease, the era of the daily pill may be drawing to a close.